Davids Hong News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MD Anderson Research Highlights for January 25, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

United statesLauren byersSimon heekeMuzaffar qazilbashDavids hongJohn heymachKonstantin sokolovXiaoxi panKevan morrisOren pasvolskyAaron schwartz duvalVinay pattalachintiMichiaki itoRugang zhangJohn paul shenMolecular cancer research

MD Anderson Unveils Key Research Highlights for Jan 25, 2024

MD Anderson Unveils Key Research Highlights for Jan 25, 2024
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesLauren byersSimon heekeMuzaffar qazilbashDavids hongJohn heymachKonstantin sokolovXiaoxi panKevan morrisOren pasvolskyVinay pattalachintiAaron schwartz duvalMichiaki itoRugang zhangJohn paul shenNational cancer institute

MD Anderson Research Highlights for January 25, 2024

MD Anderson Research Highlights for January 25, 2024
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

United statesJohn paul shenMichiaki itoRugang zhangVinay pattalachintiAaron schwartz duvalKevan morrisOren pasvolskyXiaoxi panJohn heymachKonstantin sokolovDavids hongLauren byersSimon heekeMuzaffar qazilbashMolecular cancer research

Novel KRAS G12C Inhibitor Reflects Research Advances in NSCLC and CRC

David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.

San antonioUnited statesGenentech rocheAdrian sacherMount everestDavids hongDavid sommerhalderOncologic drugs advisory committee meetingOncologic drugs advisory committeeUniversity of texas md anderson cancer centerDepartment of investigational cancer therapeuticsDivision of cancer medicineInternational conference on molecularMolecular targetsCancer therapeuticsInvestigational cancer therapeutics

Dr Hong on Preliminary Activity With RMC-6291 in Advanced KRAS G12C–Mutant Solid Tumors

David S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.

United statesDavids hongDivision of cancer medicineDepartment of investigational cancer therapeuticsUniversity of texas md anderson cancer centerInvestigational cancer therapeuticsCancer medicineCancer centerTherapeutics annual meetingRmc 6291Ras g12c inhibitor phase 1 trial nct05462717Advanced kras g12c mutant solid tumors